Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 2/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1715 | 0.86 | LMNA (0.59) | LMNAHSD17B10HTR1AADRA1ACYP2C19 | |
| SCHEMBL65737 | 0.86 | LMNA (0.59) | LMNAHSD17B10HTR1AADRA1ACYP2C19 | |
| SCHEMBL67237 | 0.86 | LMNA (0.59) | LMNAHSD17B10HTR1AADRA1ACYP2C19 | |
| SCHEMBL29757088 | 0.86 | LMNA (0.59) | LMNAHSD17B10HTR1AADRA1ACYP2C19 | |
| SCHEMBL20769804 | 0.86 | LMNA (0.59) | LMNAHSD17B10HTR1AADRA1ACYP2C19 | |
| SCHEMBL9171150 | 0.84 | LMNA (0.58) | LMNAHSD17B10HTR1AADRA1ACYP2C19 | |
| Hydrochloric Acid SCHEMBL2008283 | 0.84 | LMNA (0.58) | LMNAHSD17B10HTR1AADRA1ACYP2C19 | |
| SCHEMBL5598361 | 0.84 | LMNA (0.58) | LMNAHSD17B10HTR1AADRA1ACYP2C19 | |
| Hydrochloric Acid SCHEMBL16820451 | 0.84 | LMNA (0.58) | LMNAHSD17B10HTR1AADRA1ACYP2C19 | |
| Methane SCHEMBL7338694 | 0.84 | LMNA (0.58) | LMNAHSD17B10HTR1AADRA1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9480750-B2 | Preparation of antibody or an antibody fragment targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof | GEORGETOWN UNIVERSITY (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150224201-A1 | PREPARATION OF ANTIBODY OR AN ANTIBODY FRAGMENT TARGETED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2015-08-13 | — | — | US | disclosed |
| US-9034330-B2 | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof | GEORGETOWN UNIVERSITY (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140363491-A1 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO., LTD. (JP) | 2014-12-11 | — | — | US | disclosed |
| EP-1863448-B1 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-8758810-B2 | Liposome compositions | MEBIOPHARM CO., LTD. (JP) | 2014-06-24 | — | — | US | disclosed |
| US-20110081404-A1 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO., LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
| US-7829113-B2 | comprising one or more phosphatidylcholines, an N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug, cholesterol; cancer treatment | MEBIOPHARM CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| EP-2023897-A1 | PREPARATION OF ANTIBODY OR AN ANTIBODY FRAGMENT-TARGETED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS AND USES THEREOF | GEORGETOWN UNIVERSITY (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008030818-A2 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO., LTD. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2007142781-A1 | PREPARATION OF ANTIBODY OR AN ANTIBODY FRAGMENT-TARGETED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS AND USES THEREOF | GEORGETOWN UNIVERSITY (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070231378-A1 | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof | GEORGETOWN UNIVERSITY (US) | 2007-10-04 | — | — | US | disclosed |
| US-20060222696-A1 | comprising one or more phosphatidylcholines, an N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug, cholesterol; cancer treatment | MEBIOPHARM CO., LTD. (JP) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060222696-A1 | comprising one or more phosphatidylcholines, an N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug, cholesterol; cancer treatment | PHOSPHO1, SGMS2, SGMS1 | LMNA 647/4885HSD17B10 587/4885HTR1A 3419/4885 |
| US-20150224201-A1 | PREPARATION OF ANTIBODY OR AN ANTIBODY FRAGMENT TARGETED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS AND USES THEREOF | CHMP4B, PLTP, FCGRT | LMNA 821/4885HSD17B10 4489/4885HTR1A 4784/4885 |
| US-20070231378-A1 | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof | CHMP4B, PLTP, PCTP | LMNA 791/4885HSD17B10 4529/4885HTR1A 4766/4885 |
| US-20140363491-A1 | NOVEL LIPOSOME COMPOSITIONS | PHOSPHO1, LIPA, LYPLAL1 | LMNA 1324/4885HSD17B10 2042/4885HTR1A 4531/4885 |
| US-20110081404-A1 | NOVEL LIPOSOME COMPOSITIONS | PHOSPHO1, LIPA, LYPLAL1 | LMNA 1324/4885HSD17B10 2042/4885HTR1A 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.